Where Honda’s CRF300 Rally is the class-leader for rally-style trailies, it finally has some competition from Chinese brand Voge and their Rally 300. For those of you who haven’t heard of Voge ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

300 is a 2007 fantasy war movie directed by Zack Snyder, which is based on a graphic novel of the same name by Frank Miller. The graphic novel and the movie tell the true story of King Leonidas I ...

Your browser does not support the audio element. After a few recent spy sightings, the Apache RTX 300 adventure bike has been leaked from the show floor at the ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Despite Eylea's market challenges, Dupixent's strong performance and future potential in COPD, along with a robust pipeline, position Regeneron for recovery in 2025. Regeneron's solid financials ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

The World Bank Group is partnering with the African Development Bank and other partners on Mission 300, an ambitious initiative to connect 300 million people to electricity in Sub-Saharan Africa by ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

Because we've not been in a full launch mode for some years but with ALTUVIIIO, with Beyfortus, with Dupixent, I think we're showing people we know what we're doing. First off. Secondly ...